Safety and immunogenicity evaluation of recombinant E.coli BK-SE36 malaria vaccine candidate with aluminium hydroxide gel as adjuvant administered either subcutaneously or intramuscularly in healthy malaria exposed African children living in Burkina Faso: A double blinded, randomized, controlled, age de-escalating, phase Ib clinical trial.
Phase of Trial: Phase I
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Malaria vaccine (Primary) ; Malaria vaccine (Primary) ; Aluminium hydroxide; Aluminium hydroxide
- Indications Falciparum malaria
- Focus Adverse reactions
- Sponsors Nobelpharma
- 04 Apr 2017 Status changed from active, no longer recruiting to discontinued.
- 16 Sep 2016 New trial record